For the quarter ending 2026-03-31, MDGL had $28,405K increase in cash & cash equivalents over the period. -$171,284K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -94,391 | -58,575 | -114,190 | -115,519 |
| Stock-based compensation expense | 34,018 | 25,788 | 26,252 | 46,090 |
| Depreciation and amortization expense | 386 | 392 | 358 | 756 |
| Amortization of debt issuance costs and discount | 449 | 468 | 329 | 807 |
| Amortization and interest accretion related to operating leases | 408 | 1,548 | 1,551 | 111 |
| Loss on extinguishment of debt | - | 0 | -2,779 | - |
| Other non-cash items, net | 3,052 | - | 330 | -942 |
| Trade receivables, net | 52,880 | 21,191 | 34,054 | 25,409 |
| Prepaid expenses and other assets | 40,649 | -1,525 | -9,275 | 44,818 |
| Inventory | 22,187 | 1,729 | 5,820 | 29,429 |
| Accounts payable | 3,584 | 4,942 | 5,961 | -5,624 |
| Accrued liabilities | 4,287 | -88,419 | 187,537 | 32,784 |
| Accrued interest, net of interest received on maturity of investments | 1,980 | 2,403 | 202 | 3,366 |
| Acquisition of intangible asset | - | 0 | 3,000 | 0 |
| Net cash used in operating activities | -167,435 | -133,460 | 79,850 | -135,943 |
| Purchases of marketable securities | 157,829 | 212,956 | 478,208 | 356,346 |
| Sales and maturities of marketable securities | 353,869 | 240,146 | 275,069 | 568,082 |
| Purchases of property and equipment, net of disposals | 3,849 | -390 | 857 | 0 |
| Net cash provided by investing activities | 192,191 | 27,580 | -206,996 | 211,736 |
| Proceeds from issuance or sale of equity-Nonrelated Party | - | 0 | 0 | 0 |
| Proceeds from issuance or sale of equity-Related Party | - | 9,939 | 17,735 | 10,381 |
| Proceeds from issuance of debt | - | 0 | 350,000 | - |
| Payment of debt issuance costs | - | 983 | 9,424 | - |
| Repayment of debt | - | 0 | 121,664 | - |
| Proceeds from exercise of common stock options | 2,329 | - | - | - |
| Net cash provided by financing activities | 2,329 | 8,956 | 236,647 | 10,381 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 1,320 | 13 | - | - |
| Net increase in cash, cash equivalents, and restricted cash | 28,405 | -96,911 | 109,501 | 86,174 |
| Cash, cash equivalents, and restricted cash at beginning of period | 300,694 | - | 105,019 | - |
| Cash, cash equivalents, and restricted cash at end of period | 232,188 | - | 300,694 | - |
MADRIGAL PHARMACEUTICALS, INC. (MDGL)
MADRIGAL PHARMACEUTICALS, INC. (MDGL)